Delgocitinib Maintains QOL, Productivity Improvements at 52 Weeks in Chronic Hand Eczema

Why It Matters

Sustained HRQOL and productivity benefits demonstrate that delgocitinib can reduce the long‑term socioeconomic burden of chronic hand eczema, offering dermatologists a viable alternative to steroids.

Key Takeaways

• Delgocitinib maintained DLQI improvement of 8.5 points at 52 weeks
• Work productivity loss fell from 44% baseline to 19% after one year
• As‑needed dosing preserved quality‑of‑life gains without increased adverse events
• 86 patients with baseline absenteeism saw 15.4‑point reduction

Pulse Analysis

Chronic hand eczema affects roughly 5 % of adults and is a leading cause of occupational disability in skin‑related disorders. The condition’s hallmark itch, pain, and visible lesions impair daily activities, sleep, and mental health, driving patients to seek more than basic moisturizers or short‑term corticosteroids. Payers and employers bear hidden costs through absenteeism and reduced productivity, prompting a search for therapies that deliver durable symptom control while minimizing systemic exposure.

Delgocitinib, a topical Janus kinase (JAK) inhibitor, emerged from the phase 3 DELTA 1 and DELTA 2 trials as a potent anti‑inflammatory agent that outperformed vehicle cream over 16 weeks. The DELTA 3 open‑label extension confirmed that extending treatment—initially twice‑daily, then as‑needed—sustains clinically meaningful improvements across disease‑specific (HEIS), dermatology‑specific (DLQI), and generic (EQ‑5D‑5L) health‑related quality‑of‑life instruments. Importantly, work productivity loss measured by WPAI‑CHE halved, and the subgroup with baseline absenteeism experienced a 15‑point drop, indicating real‑world functional gains beyond skin clearance.

For the dermatology market, these findings position delgocitinib as a long‑term maintenance option that can be integrated into step‑therapy protocols, potentially reducing reliance on topical steroids and their associated skin‑atrophy risks. Insurers may view the sustained productivity improvements as a cost‑offset, supporting favorable formulary placement. Future research will likely explore head‑to‑head comparisons with emerging biologics and assess real‑world adherence to as‑needed dosing schedules, shaping the therapeutic landscape for chronic hand eczema over the next decade.